Skip to main content
. 2006 Nov 20;150(1):19–28. doi: 10.1038/sj.bjp.0706960

Figure 5.

Figure 5

Effects of raloxifene (RAL) and Y134 on mammary gland terminal end bud (TEB) outgrowth. Ovariectomized rats were treated with 17β-oestradiol (E2) in conjunction with a daily oral dose of either RAL or Y134. The upper panel shows: (a) sham-operated group given vehicle only (negative control); (b) ovariectomized rats given vehicle only; (c) ovariectomized rats supplemented with E2 alone; (d) ovariectomized rats administered both E2 and RAL (3 mg kg−1 day−1); (e) ovariectomized rats administered both E2 and Y134 (3 mg kg−1 day−1) and (f) ovariectomized rats administered both E2 and Y134 (1 mg kg−1 day−1). The mammary glands were dissected out, fixed, stained and photographed as described in Methods (magnification × 30). The lower panel represents a quantitative analysis of the above observation by counting TEB from five fields, randomly selected, under a stereo microscope. Positive score was given when rami counted were more than four and percentage of the positive TEB calculated are based on an average reading of five fields. SHAM, sham-operated; OVX, ovariectomized. **P<0.01 compared between OVX and E2, E2 and E2+RAL, E2 and E2+Y134, and E2+RAL and E2+Y134 (3 mg), respectively.